Ovarian Cancer

A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, describes the current indications for PARP inhibitors in ovarian cancer.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.

Bradley Monk, MD, FACOG, FACS, a professor at the University of Arizona, chronicles the regulatory changes in PARP inhibitors as they gain more indications in ovarian cancer.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, shares his experience mitigating the potential side effects of PARP inhibitors in ovarian cancer treatment.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.

A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.

Kazia Therapeutics will report the full results at a future scientific meeting.

One patient had a complete response and the majority of patients achieved disease control at 12 weeks.

New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.

Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.

The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.

The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.

Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.

Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.

A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.